EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Christof Vulsteke, Anders Ullén

New England Journal of Medicine · 18.06.2026 · 394 (23) · 2382-2383

DOI: 10.1056/nejmc2605751 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 18.06.2026. Verfasst von Christof Vulsteke und 1 weiteren Autor:innen. Beteiligte Einrichtung: AZ Maria Middelares, Ghent, Belgium. Die Arbeit nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: Vulsteke et al. (April 2 issue) 1 report a substantial 2-year event-free survival with perioperative enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer, as well as a remarkably high percentage of those who had a pathological complete response. Of note, the magnitude of pathological complete response suggests that many patients may have minimal residual disease after neoadjuvant therapy alone. Given the 100% incidence of adverse events and the high incidence of toxic effects of grade 3 or higher, the uniform addition of an adjuvant phase may not be justified. Circulating tumor DNA (ctDNA) provides a . . .

Autor:innen und Institutionen

  • AZ Maria Middelares, Ghent, Belgium.
  • Karolinska University Hospital, Stockholm.

Zitieren

APA

Vulsteke, C., & Ullén, A. (2026). Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine, 394(23), 2382-2383. https://doi.org/10.1056/nejmc2605751

Vancouver

Vulsteke C, Ullén A. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine. 2026;394(23):2382-2383. doi:10.1056/nejmc2605751

BibTeX
@article{Vulsteke2026,
  author = {Vulsteke, Christof and Ullén, Anders},
  title = {Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {23},
  pages = {2382--2383},
  doi = {10.1056/nejmc2605751}
}
Kostenlos starten →